The Association of Aging-Related Polymorphisms with Susceptibility to Lung Cancer: A Case-Control Study in a Japanese Population.
Aging
/ genetics
Carcinoma
/ genetics
Case-Control Studies
Female
Genetic Predisposition to Disease
/ genetics
Humans
Japan
Lung Neoplasms
/ genetics
Male
Polymorphism, Genetic
/ genetics
RNA
/ genetics
Telomerase
/ genetics
Telomere-Binding Proteins
/ genetics
Tumor Suppressor Protein p53
/ genetics
Tumor Suppressor p53-Binding Protein 1
/ genetics
Lung cancer
Oligonucleotide/oligosaccharide-binding fold containing 1
Telomerase reverse transcriptase
Telomere RNA component
aging
Journal
Asian Pacific journal of cancer prevention : APJCP
ISSN: 2476-762X
Titre abrégé: Asian Pac J Cancer Prev
Pays: Thailand
ID NLM: 101130625
Informations de publication
Date de publication:
01 Apr 2021
01 Apr 2021
Historique:
received:
24
01
2021
entrez:
28
4
2021
pubmed:
29
4
2021
medline:
24
11
2021
Statut:
epublish
Résumé
Telomere length is associated with cancer as well as aging. Telomerase reverse transcriptase (TERT), telomere RNA component (TERC) and oligonucleotide/oligosaccharide-binding fold containing 1 (OBFC1) are known to be involved in telomere length regulation. The tumor suppressor p53 (TP53), which has been shown to interact with tumor protein p53-binding protein 1 (TP53BP1), is implicated in the response to telomere shortening and aging. Polymorphisms in the TP53 and TP53BP1 genes are associated with various types of cancer. The aim of this study is to evaluate the impact of aging-related polymorphisms on lung cancer risk. This case-control study consists of 462 lung cancer cases and 379 controls from Japan. We examined the effect of TERT rs2736100, TERC rs1881984, OBFC1 rs11191865, TP53 rs1042522 and TP53BP1 rs560191 on the risk of lung cancer using a Taq-Man real-time PCR assay. Unconditional logistic regression was used to assess the adjusted odds ratios (ORs) and 95% confidence intervals (CIs). None of the main effects of any of the telomere-related polymorphisms were related to the risk of lung cancer. Similarly, none of the interactive effects of any of the telomere-related polymorphisms with smoking were associated with lung cancer risk. The significant multiplicative interaction between TERT rs2736100 and TP53BP1 rs560191 was statistically significant (OR for interaction = 0.34, 95% CI = 0.14-0.84). The multiplicative interaction between OBFC1 rs11191865 and TP53BP1 rs560191 was also statistically significant (OR for interaction = 2.44, 95% CI = 1.02-5.87) but the OR for interaction was in the opposite direction. Our findings indicate that TP53BP1 rs560191 may predispose to lung cancer risk depending on the genotypes of telomere-related polymorphisms. Additional studies are warranted to confirm the findings suggested in the present study.<br />.
Sections du résumé
BACKGROUND
BACKGROUND
Telomere length is associated with cancer as well as aging. Telomerase reverse transcriptase (TERT), telomere RNA component (TERC) and oligonucleotide/oligosaccharide-binding fold containing 1 (OBFC1) are known to be involved in telomere length regulation. The tumor suppressor p53 (TP53), which has been shown to interact with tumor protein p53-binding protein 1 (TP53BP1), is implicated in the response to telomere shortening and aging. Polymorphisms in the TP53 and TP53BP1 genes are associated with various types of cancer. The aim of this study is to evaluate the impact of aging-related polymorphisms on lung cancer risk.
MATERIALS AND METHODS
METHODS
This case-control study consists of 462 lung cancer cases and 379 controls from Japan. We examined the effect of TERT rs2736100, TERC rs1881984, OBFC1 rs11191865, TP53 rs1042522 and TP53BP1 rs560191 on the risk of lung cancer using a Taq-Man real-time PCR assay. Unconditional logistic regression was used to assess the adjusted odds ratios (ORs) and 95% confidence intervals (CIs).
RESULTS
RESULTS
None of the main effects of any of the telomere-related polymorphisms were related to the risk of lung cancer. Similarly, none of the interactive effects of any of the telomere-related polymorphisms with smoking were associated with lung cancer risk. The significant multiplicative interaction between TERT rs2736100 and TP53BP1 rs560191 was statistically significant (OR for interaction = 0.34, 95% CI = 0.14-0.84). The multiplicative interaction between OBFC1 rs11191865 and TP53BP1 rs560191 was also statistically significant (OR for interaction = 2.44, 95% CI = 1.02-5.87) but the OR for interaction was in the opposite direction.
CONCLUSIONS
CONCLUSIONS
Our findings indicate that TP53BP1 rs560191 may predispose to lung cancer risk depending on the genotypes of telomere-related polymorphisms. Additional studies are warranted to confirm the findings suggested in the present study.<br />.
Identifiants
pubmed: 33906323
doi: 10.31557/APJCP.2021.22.4.1279
pmc: PMC8325147
pii:
doi:
Substances chimiques
Stn1 protein, human
0
TP53 protein, human
0
TP53BP1 protein, human
0
Telomere-Binding Proteins
0
Tumor Suppressor Protein p53
0
Tumor Suppressor p53-Binding Protein 1
0
telomerase RNA
0
RNA
63231-63-0
TERT protein, human
EC 2.7.7.49
Telomerase
EC 2.7.7.49
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1279-1285Références
Exp Hematol. 2010 Oct;38(10):854-9
pubmed: 20600576
Am J Epidemiol. 2006 Feb 1;163(3):197-203
pubmed: 16339049
Cell. 1999 May 14;97(4):527-38
pubmed: 10338216
Asian Pac J Cancer Prev. 2019 Sep 01;20(9):2707-2714
pubmed: 31554367
Genet Mol Res. 2012 Feb 16;11(1):370-8
pubmed: 22370939
Sci Rep. 2017 Aug 21;7(1):8371
pubmed: 28827732
Nat Genet. 2013 Apr;45(4):422-7, 427e1-2
pubmed: 23535734
Oncotarget. 2016 Jun 21;7(25):37825-37838
pubmed: 27191258
Nature. 2002 Jan 3;415(6867):45-53
pubmed: 11780111
Asian Pac J Cancer Prev. 2020 Mar 01;21(3):667-673
pubmed: 32212792
J Cancer Res Ther. 2015 Jul-Sep;11(3):565-70
pubmed: 26458582
Nat Genet. 2010 Mar;42(3):197-9
pubmed: 20139977
PLoS One. 2014 Jul 18;9(7):e102372
pubmed: 25036724
Int J Epidemiol. 2007 Apr;36(2):439-45
pubmed: 17182636
Dan Med J. 2012 May;59(5):B4454
pubmed: 22549493
Lung Cancer. 2013 May;80(2):131-7
pubmed: 23433592
Nat Genet. 2010 Oct;42(10):893-6
pubmed: 20871597
CA Cancer J Clin. 2019 Jan;69(1):7-34
pubmed: 30620402
Trends Biochem Sci. 2002 Jul;27(7):339-44
pubmed: 12114022
Cancer Res. 2014 May 1;74(9):2476-86
pubmed: 24618342
J Natl Cancer Inst. 2012 Apr 4;104(7):541-8
pubmed: 22423009
Carcinogenesis. 2010 Feb;31(2):234-8
pubmed: 19955392
Nat Med. 2006 Oct;12(10):1133-8
pubmed: 17024208
Nat Genet. 2010 Mar;42(3):210-5
pubmed: 20139978
Cancer Sci. 2008 Jul;99(7):1385-9
pubmed: 18452563
J Biol Chem. 2009 Sep 25;284(39):26725-31
pubmed: 19648609
Nature. 2007 Jun 7;447(7145):655-60
pubmed: 17554299
Eur Heart J. 2008 Nov;29(21):2689-94
pubmed: 18762552
Science. 1963 Aug 23;141(3582):686-94
pubmed: 14024359
PLoS Genet. 2010 Aug 05;6(8):
pubmed: 20700438
Oncol Rep. 2010 May;23(5):1361-8
pubmed: 20372852